UA102120C2 - Пероральная форма дозирования бендамустина - Google Patents
Пероральная форма дозирования бендамустинаInfo
- Publication number
- UA102120C2 UA102120C2 UAA201106235A UAA201106235A UA102120C2 UA 102120 C2 UA102120 C2 UA 102120C2 UA A201106235 A UAA201106235 A UA A201106235A UA A201106235 A UAA201106235 A UA A201106235A UA 102120 C2 UA102120 C2 UA 102120C2
- Authority
- UA
- Ukraine
- Prior art keywords
- bendamustine
- pharmaceutically acceptable
- dosage forms
- oral dosage
- polyethoxylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Изобретение касается пероральной фармацевтической композиции, которая содержит бендамустин или его фармацевтически приемлемый эстер, соль или сольват как активный ингредиент и фармацевтически приемлемый наполнитель, которым является фармацевтически приемлемый неионный сурфактант, выбранный из группы: макроголь-глицерин-гидроксистеарат, полиоксил-35-касторовое масло и блок-кополимер этилен-оксида/пропилен-оксида (Pluronic® L44 NF или Poloxamer® 124).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08075915 | 2008-12-03 | ||
PCT/EP2009/008857 WO2010063493A1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Publications (1)
Publication Number | Publication Date |
---|---|
UA102120C2 true UA102120C2 (ru) | 2013-06-10 |
Family
ID=40588059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201106235A UA102120C2 (ru) | 2008-12-03 | 2009-12-03 | Пероральная форма дозирования бендамустина |
Country Status (25)
Country | Link |
---|---|
US (4) | US20120003305A1 (ru) |
EP (1) | EP2367542B1 (ru) |
JP (1) | JP5778037B2 (ru) |
KR (1) | KR101688038B1 (ru) |
CN (2) | CN102281871A (ru) |
AU (1) | AU2009321745B2 (ru) |
BR (1) | BRPI0922806B8 (ru) |
CA (1) | CA2745525A1 (ru) |
CO (1) | CO6400183A2 (ru) |
CY (1) | CY1114977T1 (ru) |
DK (1) | DK2367542T3 (ru) |
EA (1) | EA020354B1 (ru) |
ES (1) | ES2451540T3 (ru) |
HR (1) | HRP20140204T1 (ru) |
IL (1) | IL213270A (ru) |
MX (1) | MX2011005643A (ru) |
NZ (1) | NZ592970A (ru) |
PL (1) | PL2367542T3 (ru) |
PT (1) | PT2367542E (ru) |
RS (1) | RS53201B (ru) |
SI (1) | SI2367542T1 (ru) |
SM (1) | SMT201400053B (ru) |
UA (1) | UA102120C2 (ru) |
WO (1) | WO2010063493A1 (ru) |
ZA (1) | ZA201103791B (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
DK2575784T3 (en) * | 2010-06-02 | 2018-10-15 | Astellas Deutschland Gmbh | ORAL DOSAGE FORMS OF BENDAMUSTIN |
CN102375044B (zh) * | 2010-08-18 | 2015-04-08 | 重庆华邦胜凯制药有限公司 | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 |
CN104011029B (zh) * | 2011-09-26 | 2016-06-08 | 费森尤斯卡比肿瘤学有限公司 | 一种制备盐酸苯达莫司汀的改进方法 |
CA3078979C (en) | 2011-10-31 | 2022-10-11 | Genentech, Inc. | Formulation comprising an anti-il13 antibody having extended stability |
EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
SI2656843T1 (sl) | 2012-04-26 | 2015-06-30 | Helmut Schickaneder | Estri bendamustina in povezane spojine ter njihova medicinska uporaba |
SG11201503560TA (en) * | 2012-11-12 | 2015-06-29 | Ignyta Inc | Bendamustine derivatives and methods of using same |
EP2968153B1 (en) | 2013-03-12 | 2018-05-02 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
MX2016002502A (es) | 2013-08-27 | 2017-02-28 | Voudouris Vasilios | Composiciones farmaceuticas de bendamustina. |
JP7267290B2 (ja) | 2017-10-05 | 2023-05-01 | チューブ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経口ベンダムスチン製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US132502A (en) * | 1872-10-22 | Improvement in machines for removing snow from railroads | ||
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
CN101933923A (zh) * | 2004-11-05 | 2011-01-05 | 赛福伦公司 | 癌症治疗 |
CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
CN101028249A (zh) * | 2007-04-12 | 2007-09-05 | 济南康泉医药科技有限公司 | 一种含新生血管抑制剂及烷化剂的抗癌组合物 |
CN101045058A (zh) * | 2007-04-28 | 2007-10-03 | 济南帅华医药科技有限公司 | 一种含烷化剂及激素类药物的抗癌组合物 |
CN101084876A (zh) * | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
-
2009
- 2009-12-03 MX MX2011005643A patent/MX2011005643A/es active IP Right Grant
- 2009-12-03 ES ES09796303.7T patent/ES2451540T3/es active Active
- 2009-12-03 KR KR1020117015292A patent/KR101688038B1/ko active IP Right Grant
- 2009-12-03 DK DK09796303.7T patent/DK2367542T3/da active
- 2009-12-03 AU AU2009321745A patent/AU2009321745B2/en active Active
- 2009-12-03 CN CN2009801547145A patent/CN102281871A/zh active Pending
- 2009-12-03 BR BRPI0922806A patent/BRPI0922806B8/pt active IP Right Grant
- 2009-12-03 CN CN201510849775.0A patent/CN105363037B/zh active Active
- 2009-12-03 JP JP2011538906A patent/JP5778037B2/ja active Active
- 2009-12-03 PL PL09796303T patent/PL2367542T3/pl unknown
- 2009-12-03 EA EA201190011A patent/EA020354B1/ru unknown
- 2009-12-03 PT PT97963037T patent/PT2367542E/pt unknown
- 2009-12-03 WO PCT/EP2009/008857 patent/WO2010063493A1/en active Application Filing
- 2009-12-03 NZ NZ592970A patent/NZ592970A/xx unknown
- 2009-12-03 CA CA2745525A patent/CA2745525A1/en not_active Abandoned
- 2009-12-03 US US13/132,263 patent/US20120003305A1/en not_active Abandoned
- 2009-12-03 SI SI200930877T patent/SI2367542T1/sl unknown
- 2009-12-03 UA UAA201106235A patent/UA102120C2/ru unknown
- 2009-12-03 RS RS20140111A patent/RS53201B/en unknown
- 2009-12-03 EP EP09796303.7A patent/EP2367542B1/en active Active
-
2011
- 2011-05-24 ZA ZA2011/03791A patent/ZA201103791B/en unknown
- 2011-05-31 IL IL213270A patent/IL213270A/en active IP Right Grant
- 2011-06-28 CO CO11080792A patent/CO6400183A2/es not_active Application Discontinuation
-
2013
- 2013-07-01 US US13/932,785 patent/US20140018334A1/en not_active Abandoned
-
2014
- 2014-03-05 CY CY20141100174T patent/CY1114977T1/el unknown
- 2014-03-05 HR HRP20140204AT patent/HRP20140204T1/hr unknown
- 2014-04-22 SM SM201400053T patent/SMT201400053B/xx unknown
-
2015
- 2015-04-24 US US14/695,527 patent/US20150335588A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,467 patent/US10543196B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA102120C2 (ru) | Пероральная форма дозирования бендамустина | |
NZ746271A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
ATE540680T1 (de) | Pharmazeutische aripiprazol-zusammensetzungen | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
CO6531485A2 (es) | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa | |
MY177741A (en) | Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate. | |
BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
WO2010042391A3 (en) | Hiv integrase inhibitors | |
WO2007100614A3 (en) | STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR | |
WO2011101863A3 (en) | Extended release pharmaceutical compositions of lacosamide | |
WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
WO2012064302A3 (en) | Improved montelukast formulations | |
WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
PH12017502426A1 (en) | Solid pharmaceutical compositions for treating hcv | |
TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
EA201001125A1 (ru) | Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид | |
WO2011135582A3 (en) | Pharmaceutical compositions of dronedarone | |
PH12018500132A1 (en) | Solid pharmaceutical compositions for treating hcv | |
HK1163526A1 (en) | A medicament for treating schizophrenia comprising cilostazol | |
WO2011128914A3 (en) | Extended release pharmaceutical compositions of pramipexole | |
WO2020032883A3 (en) | Synergistic effects of a novel ketoprofen formulation including a gastro protective agent | |
UA110792C2 (uk) | Лікарська форма бендамустину для перорального застосування |